Creating a new treatment for Head and Neck Squamous Cell Carcinoma using antibody and RNA technology
Official title: Development of an antibody-oligonucleotide conjugate for treatment of Head and Neck Squamous Cell Carcinoma
Funded at Mirecule, INC. · NIH-11008149 · Data updated 2026-11-12
This study is testing a new treatment for advanced head and neck cancer that combines a special antibody with a modified RNA to help fight the cancer more effectively, aiming to improve outcomes for patients like you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mirecule, INC. NIH-funded |
| Lab location | 1 site (Gaithersburg, UNITED STATES) |
| Project start | September 18, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $863,708 |
| NIH project number | 1R44CA291527-01A1 |
| Project ID | NIH-11008149 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with locoregionally advanced Head and Neck Squamous Cell Carcinoma who have limited treatment options.
✕Less likely to help
Patients with early-stage Head and Neck Squamous Cell Carcinoma or those whose cancer is not responsive to EGFR-targeted therapies may not benefit from this research.
What this research studies
This research focuses on developing a novel treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) by combining an antibody, cetuximab, with a modified RNA molecule that mimics a tumor suppressor. The approach aims to target multiple growth factor receptors that cancer cells use to survive and grow, potentially improving treatment outcomes for patients with advanced disease. By using this antibody-RNA conjugate, the research seeks to enhance the effectiveness of existing therapies and address the limitations of current treatments. Patients may benefit from a more comprehensive attack on the cancer cells, which could lead to better survival rates.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with advanced Head and Neck Squamous Cell Carcinoma.
How similar studies have gone: Other research has shown promise in using antibody-RNA conjugates for cancer treatment, indicating that this approach may be viable.
Where this research is happening
-
Mirecule, INC.
Gaithersburg, United States Active
Researchers
- Principal investigator: Saleh, Anthony D — Mirecule, INC.
- Study coordinator: Saleh, Anthony D
Related research
Other NIH-funded projects on the same topics.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer
A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.
-
Targeting PIPKIγi5 to boost immune responses against head and neck cancer
A study to see if blocking a specific enzyme, PIPKIγi5, can make head and neck cancer more visible to the immune system and more responsive to existing immunotherapies.
-
Targeted approaches for lung squamous cell carcinoma with key gene changes
A study at a major university is exploring new targets in lung squamous cell carcinoma to help people with this cancer find better treatments.
-
Baculovirus-based therapy to treat head and neck cancer with a gentle, minimally invasive approach
A new, minimally invasive approach using baculovirus-delivered CRISPR gene editing aims to treat head and neck squamous cell carcinoma while aiming to preserve essential tissues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.